Brief: Xvivo Perfusion Q2 EBITDA At SEK 8.1 Million
July 12 (Reuters) - Xvivo Perfusion AB XVIVO.ST :
* HISTORIC PMA APPROVAL AND PROGRESS IN THE RESEARCH AND
DEVELOPMENT PORTFOLIO
* Q2 EBITDA SEK 8.1 MILLION VERSUS SEK 8.1 MILLION YEAR AGO
* Q2 NET SALES OF NON-DURABLE GOODS IN QUARTER AMOUNTED TO
SEK
50.5 MLN (42.2 MLN)
* Q2 NET SALES SEK 56.4 MILLION VERSUS SEK 46.1 MILLION YEAR
AGO
Source text for Eikon: ID:nWkr74y8fS
Further company coverage: XVIVO.ST
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 587720920;))
Recent news on Xvivo Perfusion AB
See all newsSweden's XVIVO Q3 revenue beat expectations on thoracic sales
Brief: Xvivo Q3 EBIT SEK 28 Million
Brief: Xvivo Receives CE Certificates For Heart Preservation Technology
Brief: XVIVO Gets FDA Approval For Additional Patient Enrollment
Sweden's XVIVO Q2 sales beat estimates, helped by thoracic segment strength